PBAC's latest decision on Cannabidiol: Noted (2025). Considered for Treatment of seizures associated with Lennox-Gastaut syndrome (LGS).
PBAC outcome
Noted
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
4
first 2020
Submissions
4
2020 → 2025
Eligible population
Patients with seizures associated with Lennox-Gastaut syndrome, as per current PBS listing criteria.
Therapy area
Neurology
Line of therapy
Not applicable
Evidence base
Other
Economic model
Not modelled
ICER note
No ICER calculated; this is a Category 3 submission requesting changes to restriction level and clinical criteria for an already-listed medicine, not a new economic evaluation.
ICER (historical)
$75k/QALY–$95k/QALY in an earlier submission (2022) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Jul 2020: Recommended with restriction · Authority Required
Mar 2022: Recommended with restriction · Authority Required
Jul 2022: Not recommended · Authority Required — ICER $95k/QALY